• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Summit Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    5/30/25 4:17:49 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SMMT alert in real time by email
    smmt-20250530
    0001599298FALSE00015992982025-05-302025-05-30

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    FORM 8-K
     
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
     
    Date of Report (Date of Earliest Event Reported): May 30, 2025
     
    Summit Therapeutics Inc.
    (Exact Name of Registrant as Specified in Its Charter)
       
    Delaware001-3686637-1979717
    (State or Other Jurisdiction
    of Incorporation)
    (Commission
    File Number)
    (IRS Employer
    Identification No.)
     
    601 Brickell Key Drive, Suite 1000, Miami, FL
    33131
    (Address of Principal Executive Offices)(Zip Code)
     
    Registrant’s Telephone Number, Including Area Code: (305) 203-2034
     
    Not applicable
    (Former Name or Former Address, If Changed Since Last Report)
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
     
    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 
    Securities registered pursuant to Section 12(b) of the Act:
    Title of Each ClassTrading Symbol(s)Name of Each Exchange on Which Registered
    Common stock, $0.01 par value per shareSMMTThe Nasdaq Stock Market LLC
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



     

    Item 8.01
    Other Events.

    On May 30, 2025, Summit Therapeutics Inc. (the “Company”) announced topline results from the Phase III clinical trial, HARMONi, the first global Phase III study evaluating ivonescimab in combination with chemotherapy. Ivonescimab in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival. Additionally, ivonescimab in combination with chemotherapy showed a positive trend in overall survival in the primary analysis without achieving a statistically significant benefit.

    A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.


    Item 9.01
    Financial Statements and Exhibits.

    (d) Exhibits

    Exhibit Number
    Description
    99.1
     Press Release, dated May 30, 2025
    104Cover Page Interactive Data File (embedded within the Inline XBRL document)




    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
     SUMMIT THERAPEUTICS INC.
      
      
    Date: May 30, 2025By:/s/ Mahkam Zanganeh
      Co-Chief Executive Officer, President and Director
      (Principal Executive Officer)

    Get the next $SMMT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SMMT

    DatePrice TargetRatingAnalyst
    6/11/2025$12.00Underperform
    Leerink Partners
    3/26/2025$23.00 → $35.00Neutral → Buy
    Citigroup
    3/21/2025Overweight
    Cantor Fitzgerald
    3/12/2025$30.00Outperform
    Evercore ISI
    2/28/2025$42.00Buy
    Goldman
    1/8/2025$35.00Buy
    Truist
    12/11/2024$30.00Overweight
    Wells Fargo
    12/6/2024$31.00Buy
    Jefferies
    More analyst ratings

    $SMMT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Zanganeh Mahkam bought $411,094 worth of shares (110,321 units at $3.73), increasing direct ownership by 5% to 520,814 units (SEC Form 4)

      4 - Summit Therapeutics Inc. (0001599298) (Issuer)

      3/27/24 8:28:30 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dhingra Ankur bought $375,000 worth of shares (100,000 units at $3.75) (SEC Form 4)

      4 - Summit Therapeutics Inc. (0001599298) (Issuer)

      3/27/24 8:27:03 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zanganeh Mahkam exercised 805,495 in-the-money shares at a strike of $1.49 and bought $10,350 worth of shares (5,000 units at $2.07) (SEC Form 4)

      4 - Summit Therapeutics Inc. (0001599298) (Issuer)

      12/13/23 5:11:56 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care